To evaluate the in vitro effects of sunitinib malate and meloxicam in isolation, and to analyse the ability ofmeloxicam to enhance the cytotoxicity of sunitinib malate in three human bladder-cancer cell lines. Celllines were treated with sunitinib malate and meloxicam, either in isolation or combined. Leishman staining,MTT method, comet assay, MDC staining and M30 CytoDEATH antibody were performed. The Chouand Talalay method was applied. Sunitinib malate and meloxicam supressed cell proliferation in bladdercancercells in isolation, in a concentration-dependent manner. Treatment of bladder-cancer cells with acombination of sunitinib malate and meloxicam showed a synergistic effect. When exploring the mechanismof this combination by means of comet assay, there is the suggestion that meloxicam increases sunitinibmalate cytotoxicity through DNA damage. Autophagic and apoptotic studies show a greater incidence ofautophagic vacuoles and early apoptotic cells when the combined treatment was put into use. In isolation,sunitinib malate and meloxicam demonstrated anti-tumour effects in our study. Furthermore, simultaneousexposure of cells to sunitinib malate and meloxicam provided a combinatorial beneficial effect. This hints atthe possibility of a new combined therapeutic regimen, which could lead to improvements in the treatmentof patients with bladder cancer